Full-Time

LC/Q-TOF Product Manager

Posted on 3/12/2025

Agilent Technologies

Agilent Technologies

10,001+ employees

eProcurement solutions for streamlined purchasing

Compensation Overview

$159.7k - $249.6kAnnually

+ Bonus + Stock

Senior, Expert

Company Does Not Provide H1B Sponsorship

Santa Clara, CA, USA

This position requires more than 25% travel, including international travel.

Category
Product Management
Product
Required Skills
Sales
Product Management
Marketing
Requirements
  • Bachelors or equivalent University Degree
  • 8 + years demonstrated ability with Product Management/Marketing/Sales of mass spectrometry instruments
  • Technical knowledge of LC/MS instrumentation
  • Knowledge of customer workflows and applications within Biopharma and Life Science Research market
  • Outstanding interpersonal and communication skills
  • Ability to connect with a global team, with individuals at all levels in the organization and across multiple functions (finance, marketing, legal, R&D, product support, sales, executive leadership)
  • Past success working collaboratively with sales and marketing professionals across the organization to develop effective market strategies and programs that meet revenue forecasts and growth targets
  • Ability to travel worldwide; more than 25% travel required, including international travel
Responsibilities
  • Work with worldwide customers, industry influencers, and experts across Agilent's businesses to gain knowledge of customer workflow, worldwide market trends, and MS technologies
  • Develop detailed product definitions and requirements for R&D product development based on analysis/understanding of customer workflow needs through Voice of Customer (VOC) feedback, and market trends
  • Conduct market and competitive analysis to strategically evaluate new market opportunities and partner with internal teams to identify products that can improve customer workflows
  • Partner with a cross-functional team to align on product development across R&D, marketing, finance, manufacturing, customer support, and sales
  • Build marketing campaigns and compelling collateral to highlight value proposition and differentiation for the product

Agilent Technologies provides electronic procurement services that help businesses streamline their purchasing processes. Their main offerings include a suite of eProcurement services that allow clients to integrate their pricing into existing platforms, access a hosted catalog, and conduct transactions without paper. This system enables businesses to quickly find and purchase the products they need at the right price, enhancing productivity through automation and simplified workflows. Unlike many competitors, Agilent focuses on reliability and quality, serving a diverse range of clients with tailored solutions that lead to lower costs and increased profitability. The goal of Agilent Technologies is to improve business efficiency and productivity through effective eProcurement solutions.

Company Size

10,001+

Company Stage

IPO

Headquarters

Santa Clara, California

Founded

1999

Simplify Jobs

Simplify's Take

What believers are saying

  • Acquisitions like Sigsense enhance Agilent's AI capabilities in lab operations.
  • The trend towards paperless transactions boosts Agilent's service efficiency and appeal.
  • Automation in procurement is expected to increase, benefiting Agilent's offerings.

What critics are saying

  • Integration challenges from acquiring BIOVECTRA may disrupt Agilent's operations.
  • Multiple acquisitions could stretch Agilent's resources and management focus.
  • Increased competition from funded companies like RareCyte and Elegen may challenge Agilent.

What makes Agilent Technologies unique

  • Agilent offers a comprehensive suite of eProcurement services for streamlined purchasing.
  • The company focuses on automation and paperless transactions to enhance business productivity.
  • Agilent's hosted catalog and pricing integration simplify procurement processes for clients.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Remote Work Options

Performance Bonus

Stock Options

Growth & Insights and Company News

Headcount

6 month growth

5%

1 year growth

5%

2 year growth

5%
Business Wire
Jul 30th, 2024
Agilent Acquires Sigsense, Creator of AI-Enabled Lab Operations Technology

Agilent has acquired Sigsense Technologies, a startup that uses artificial intelligence and power monitoring to optimize lab operations.

Biovectra
Jul 22nd, 2024
Agilent Technologies to Acquire BIOVECTRA Inc., Creating New Synergistic Opportunities to Improve Patient Care | BIOVECTRA

CHARLOTTETOWN, Prince Edward Island and SANTA CLARA, California – July 22, 2024 BIOVECTRA Inc. and Agilent Technologies, Inc. (NYSE: A) today announced the signing of an agreement for Agilent to acquire BIOVECTRA, a Canadian-based Contract Development and Manufacturing Organization, from H.I.G. Capital for $925 million. The acquisition provides the ability to expand the range of [...]Read More...

Finsmes
Jun 27th, 2024
RareCyte Secures $20M Financing

RareCyte, a Seattle, WA-based Life Sciences company providing precision biology platforms including instruments, reagents, software, and services, raised $20M in funding

Business Wire
May 14th, 2024
Elegen Raises $35 Million In Series B To Accelerate Expansion Into Clinical Manufacturing

SAN CARLOS, Calif.--(BUSINESS WIRE)--Elegen, the leader in next-generation DNA synthesis and production, today announced a Series B financing of $35 million led by Triatomic Capital. Also joining the round are strategic investors GSK, which recently entered a collaboration and licensing agreement with Elegen to use their proprietary cell-free DNA manufacturing technology in developing GSK’s vaccines and medicines, and John Ballantyne, co-founder of Aldevron. Elegen’s current investors, including Andreessen Horowitz (a16z Bio + Health), KdT Ventures, 8VC, Digitalis Ventures, ACVC Partners, Alix Ventures, AME Cloud Ventures and Agilent Technologies, also participated. The new funds will accelerate the extension of the company’s rapidly growing ENFINIA™ DNA product line across clinical workflows providing turnkey production of GMP-compliant DNA for clinical development of genetic medicines. “The age of genetic medicines is here, but these powerful modalities require innovative new manufacturing approaches to supply the critical input DNA material for rapid discovery, development and then wide-scale production,” said Matthew Hill, Ph.D., Elegen Founder and CEO. “With this investment, we will continue to push the boundaries of DNA synthesis to accelerate upstream discovery and enable rapid and streamlined deployment of new clinical modalities.”

GenomeWeb
Apr 3rd, 2024
Biofidelity Raises $24M to Expand US Commercialization of Lung Cancer Test, Product Pipeline

The firm said it also plans to use the money, which brings its total raised to $60 million, to establish a dedicated manufacturing facility in the UK.